GlassScriptPhysician profile
Darion Showell
NPI 1740629096
$2,275.67
in general payments reported to CMS, 2019-2025
19 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $366 · 2022: $704 · 2023: $242 · 2024: $616 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.29 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.43 | 2020-2024 | Tagrisso, Calquence |
| Daiichi Sankyo INC. | $301.93 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $266.49 | 2022-2024 | Libtayo |
| Janssen Biotech, INC. | $198.71 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Seagen INC. | $180.30 | 2022 | |
| Eisai INC. | $141.02 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $138.04 | 2020-2024 | |
| Genentech USA, INC. | $120.26 | 2022-2023 | Tecentriq |
| Alexion Pharmaceuticals, INC. | $109.98 | 2019 | |
| Merck Sharp & Dohme LLC | $105.76 | 2022-2023 | Keytruda, Lynparza |
| Abbvie INC. | $104.47 | 2024-2025 | |
| Celgene Corporation | $64.92 | 2022-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $61.34 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.97 | 2022-2023 | Opdivo |
| Progenics Pharmaceuticals, INC. | $21.49 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $17.92 | 2022 | |
| Genzyme Corporation | $16.93 | 2022 | |
| Incyte Corporation | $15.09 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.62 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darion Showell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.